Data gathered: November 30
Alternative Data for Aclaris Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,946 | Sign up | Sign up | Sign up |
| Twitter Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 52 | Sign up | Sign up | Sign up |
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
| Price | $4.07 |
| Target Price | Sign up |
| Volume | 1,010,000 |
| Market Cap | $273M |
| Year Range | $1.01 - $4.59 |
| Dividend Yield | 0% |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26 - Yahoo |
 |
Equities Analysts Set Expectations for ACRS FY2024 EarningsNovember 25 - ETF Daily News |
 |
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Leerink Partnrs to “Strong-Buy” RatingNovember 21 - ETF Daily News |
|
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Piper SandlerNovember 21 - ETF Daily News |
 |
Aclaris Therapeutics And 2 Other US Penny Stocks To WatchNovember 21 - Yahoo |
|
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink PartnersNovember 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 4.3M | 650,000 | 3.7M | -7.6M | 0 | -0.110 |
| Q2 '24 | 2.8M | 620,000 | 2.1M | -11M | -12M | -0.150 |
| Q1 '24 | 2.4M | 810,000 | 1.6M | -17M | -13M | -0.240 |
| Q4 '23 | 18M | 730,000 | 17M | -1.5M | -4M | -0.020 |
| Q3 '23 | 9.3M | 850,000 | 8.4M | -29M | -32M | -0.410 |
Insider Transactions View All
| Mehra Anand filed to buy 710,030 shares at $2.3. November 20 '24 |
| Leonard Braden Michael filed to buy 14,250,000 shares at $1.2. August 5 '24 |
| Leonard Braden Michael filed to buy 14,043,975 shares at $1.3. August 5 '24 |
| Leonard Braden Michael filed to buy 13,876,421 shares at $1.3. July 31 '24 |
| Leonard Braden Michael filed to buy 13,776,421 shares at $1.3. July 31 '24 |
Similar companies
Read more about Aclaris Therapeutics (ACRS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Aclaris Therapeutics?
The Market Cap of Aclaris Therapeutics is $273M.
What is the current stock price of Aclaris Therapeutics?
Currently, the price of one share of Aclaris Therapeutics stock is $4.07.
How can I analyze the ACRS stock price chart for investment decisions?
The ACRS stock price chart above provides a comprehensive visual representation of Aclaris Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aclaris Therapeutics shares. Our platform offers an up-to-date ACRS stock price chart, along with technical data analysis and alternative data insights.
Does ACRS offer dividends to its shareholders?
As of our latest update, Aclaris Therapeutics (ACRS) does not offer dividends to its shareholders. Investors interested in Aclaris Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Aclaris Therapeutics?
Some of the similar stocks of Aclaris Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.